Vanguard Personalized Indexing Management LLC Trims Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Vanguard Personalized Indexing Management LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 18.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 203,673 shares of the company's stock after selling 47,221 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Kenvue were worth $4,385,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Clearstead Advisors LLC purchased a new position in Kenvue during the third quarter valued at $25,000. Planned Solutions Inc. purchased a new position in shares of Kenvue in the 4th quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Kenvue in the 4th quarter worth about $28,000. EverSource Wealth Advisors LLC purchased a new position in shares of Kenvue in the 3rd quarter worth about $28,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Kenvue in the 3rd quarter worth about $28,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of NYSE KVUE traded down $0.09 during midday trading on Wednesday, reaching $20.54. 97,655,066 shares of the stock traded hands, compared to its average volume of 18,019,373. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The stock has a market capitalization of $39.33 billion and a PE ratio of 26.33. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.77. The company's 50 day moving average is $20.02 and its 200 day moving average is $20.16.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.25 by $0.03. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. Kenvue's quarterly revenue was down 24.9% on a year-over-year basis. On average, equities research analysts anticipate that Kenvue Inc. will post 1.18 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 3.89%. Kenvue's payout ratio is 102.56%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several research analyst reports. The Goldman Sachs Group initiated coverage on Kenvue in a report on Friday, March 1st. They issued a "neutral" rating and a $20.00 price objective for the company. William Blair initiated coverage on Kenvue in a report on Wednesday, April 3rd. They issued a "market perform" rating for the company. HSBC lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a "hold" rating in a report on Wednesday, May 8th. Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They issued an "underperform" rating and a $18.00 price objective for the company. Finally, Royal Bank of Canada reduced their price objective on Kenvue from $25.00 to $24.00 and set an "outperform" rating for the company in a report on Friday, February 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Kenvue has a consensus rating of "Hold" and a consensus price target of $24.38.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.